Molecular devices lowers third quarter guidance.
Earlier this year, the company reduced its year-end fiscal guidance (see IBO 8/31/06). In its second quarter conference call, Molecular Devices reported disappointing sales results for its imaging business, citing a highly competitive market, emerging applications, a long sales cycle and delayed purchasing decisions. In addition, the company discussed a quarterly sales decline for its genomic detection products.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Executive Briefing: News, Trends & Market Intelligence for Instrument Executives|
|Publication:||Instrument Business Outlook|
|Date:||Sep 30, 2006|
|Previous Article:||Instruments' role in the biofuels roadmap.|
|Next Article:||Thermo acquires maker of online elemental analyzers.|